PharmaJet, Inc., headquartered in the United States, is a pioneering company in the biopharmaceutical industry, specialising in needle-free injection technology. Founded in 2009, PharmaJet has made significant strides in enhancing vaccine delivery systems, particularly in regions where traditional methods may pose challenges. The company’s core product, the PharmaJet Stratis® device, offers a unique, efficient, and pain-free method for administering vaccines, making it particularly valuable in global health initiatives. With a strong focus on innovation, PharmaJet has positioned itself as a leader in the market, contributing to improved vaccination rates and patient comfort. Notable achievements include partnerships with various health organisations, underscoring its commitment to advancing public health through cutting-edge technology.
How does PharmaJet, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
PharmaJet, Inc.'s score of 17 is lower than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
PharmaJet, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that PharmaJet may not have established formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. As the industry increasingly prioritises sustainability, it will be essential for PharmaJet to consider developing and communicating its climate commitments to align with broader environmental goals.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
PharmaJet, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
